Diabetic nephropathy is a growing health concern with characteristic sterile inflammation. As the underlying mechanisms of this inflammation remain poorly defined, specific therapies targeting sterile inflammation in diabetic nephropathy are lacking. Intriguingly, an association of diabetic nephropathy with inflammasome activation has recently been shown, but the pathophysiological relevance of this finding remains unknown. Within glomeruli, inflammasome activation was detected in endothelial cells and podocytes in diabetic humans and mice and in glucose-stressed glomerular endothelial cells and podocytes in vitro. Abolishing Nlrp3 or caspase-1 expression in bone marrow-derived cells fails to protect mice against diabetic nephropathy. Conversely, Nlrp3-deficient mice are protected against diabetic nephropathy despite transplantation of wild-type bone marrow. Pharmacological IL-1R antagonism prevented or even reversed diabetic nephropathy in mice. Mitochondrial reactive oxygen species (ROS) activate the Nlrp3 inflammasome in glucose or advanced glycation end product stressed podocytes. Inhibition of mitochondrial ROS prevents glomerular inflammasome activation and nephropathy in diabetic mice. Thus, mitochondrial ROS and Nlrp3-inflammasome activation in non-myeloid-derived cells aggravate diabetic nephropathy. Targeting the inflammasome may be a potential therapeutic approach to diabetic nephropathy.
Diabetic nephropathy is the leading cause of end-stage renal disease in adults, putting an enormous burden on affected individuals and health-care systems. Current therapies are insufficient, necessitating the search for new therapeutic strategies in diabetic nephropathy. Inflammatory processes have been identified as potential modulators of diabetic nephropathy. Accumulation of macrophages or T cells has been demonstrated in humans with and in rodent models of diabetic nephropathy. 1, 2 The extent of inflammatory cell accumulation in the kidney is associated with the decline of renal function, suggesting a causative link. [1] [2] [3] [4] Indeed, inhibition of inflammatory cell recruitment into the kidney has been shown to be protective in experimental diabetic nephropathy. 5, 6 Local generation of pro-inflammatory cytokines, such as interleukin 1b (IL-1b), contributes to inflammatory cell recruitment. 3, 7 Cytokines are thought to be released from activated immune cells. 3, 7 However, renal cells, such as podocytes, endothelial cells, or mesangial cells, can likewise secrete pro-inflammatory cytokines and may thus aggravate diabetic nephropathy. [8] [9] [10] [11] However, whether non-myeloid-derived glomerular resident cells promote diabetic nephropathy by secreting cytokines and how cytokine secretion from these cells may be controlled remain unknown.
The release of the pro-inflammatory cytokines IL-1b and IL-18 is controlled by the inflammasome. Various danger signals, including mitochondrial reactive oxygen species (ROS), activate the Nlrp3 (nucleotide-binding domain and leucine-rich repeat pyrin 3 domain) inflammasome. 12, 13 Upon detecting cellular stress, Nlrp3 recruits and assembles with ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) and caspase-1, resulting in caspase-1 activation, maturation of IL-1b and IL-18, and promotion of inflammatory cell recruitment. 14 Although initially thought to be restricted to immune cells it has been recently shown that the inflammasome can be functional in nonimmune cells, including podocytes. 11, 13, 15 In addition, inflammasome activation has lately been demonstrated in diabetic nephropathy, 16 but the pathophysiological relevance and the mechanism of inflammasome activation in diabetic nephropathy remain elusive. Likewise, the potential involvement of glomerular resident cells, such as podocytes or endothelial cells, for inflammasome activation in diabetic nephropathy remains unknown. To address these questions we evaluated the role of inflammasome activation in glomerular cells in the current study. Answering these questions may be of therapeutic relevance, as the inflammasome is amendable to therapeutic interventions. 17 
RESULTS

The onset of diabetic nephropathy is associated with renal inflammasome activation
To evaluate the relevance of the inflammasome in diabetic nephropathy we analyzed diabetic mice of various ages. Levels of (cleaved) IL-1b and IL-18 were low in plasma ( Figure 1a ) and hardly detectable in renal cortex extracts (Figure 1b and c) of 4-week-old db/db mice, but significantly increased in 8-and 12-week-old db/db mice. In parallel, Nlrp3 and cleaved caspase-1 levels increased, while nephrin expression declined in renal cortex extracts of db/db mice with age (Figure 1b and c) . Thus, inflammasome activation occurs at an early stage of nephropathy in db/db mice. 18 Albuminuria and glomerular extracellular matrix accumulation (FMA, fractional mesangial area) were significantly increased in 12, but not in 8-week-old db/db mice ( Figure 1d and e and Supplementary Figure S1a The renal inflammasome activation observed in db/db mice could reflect insulin resistance and obesity 19, 20 and may thus be independent of renal pathology. To address this possibility we analyzed mice with persistent hyperglycemia in the absence of obesity or insulin resistance (streptozotocin (STZ) model). In these mice albuminuria and loss of nephrin expression were likewise associated with an early increase of Hence, renal inflammasome activation is independent of obesity and insulin resistance.
Next, we analyzed markers of inflammasome activation in type 2 diabetic patients in a pilot study. In albuminuric diabetic patients, serum IL-1b levels were significantly increased compared with diabetic patients without albuminuria or nondiabetic controls (Figure 3a ) and the degree of albuminuria correlated with serum IL-1b (Figure 3b ). This correlation remained stable after correcting for age, sex, and disease duration. Furthermore, Nlrp3 expression was on average increased in glomeruli of albuminuric diabetic patients compared to diabetic patients without albuminuria or nondiabetic controls (Figure 3c and d).
Inflammasome inhibition ameliorates diabetic nephropathy in mice
To explore the functional relevance of inflammasome activation in diabetic nephropathy we induced persistent hyperglycemia in uninephrectomized Nlrp3 À / À or caspase-1 À / À mice using STZ. Nlrp3 or caspase-1 deficiency ameliorated albuminuria and the FMA without affecting the body weight or blood glucose levels ( Figure 4 and Supplementary Figure  S3 online), establishing a functional role of inflammasome activation in diabetic nephropathy. Pathological sequelae of inflammasome activation are frequently amendable to therapeutic approaches. 17 Application of the IL-1 receptor antagonist anakinra in hyperglycemic mice with insulin resistance (db/db mice) or insulinopenia (STZ model) reduced albuminuria and FMA (Figure 5a and b). Treatment with anakinra (for 12 weeks) reduced the body weight and blood glucose levels in db/db mice, but not in insulinopenic mice (STZ model, Supplementary Figure S4a -c online), illustrating that anakinra can ameliorate diabetic nephropathy independent of its metabolic effects. Of note, in 12-week-old db/db mice with established nephropathy 18 (and current data) the intervention with anakinra for 8 weeks normalized albuminuria and FMA (Figure 5c ). Thus, inhibition of IL-1 receptor signaling can not only prevent, but also reverse, diabetic nephropathy in mice.
Hyperglycemia triggers inflammasome activation in glomerular cells
Whether inflammasome activation occurs in glomerular cells in diabetic nephropathy and the potential implications of this remained unknown hitherto. Using confocal microscopy we observed partial colocalization of Nlrp3 or cleaved caspase-1 with podocytes and glomerular endothelial cells in histological sections of diabetic humans or mice, respectively (Figure 6a In vitro glucose, but not mannitol, induced Nlrp3 expression cell-autonomously and cleaved IL-1b in glomerular endothelial cells and podocytes (Figure 6c ). Furthermore, cleaved IL-1b was readily observed in primary podocytes isolated from C57BL/6 wild-type mice and was induced following glucose, but not mannitol, treatment (Figure 6d ). Of note, only pro-IL-1b, but not cleaved IL-1b, could be detected in primary podocytes isolated from caspase-1 (Figure 6d ), consistent with cell-autonomous maturation of IL-1b in podocytes.
Inflammasome deficiency in bone marrow-derived cells fails to ameliorate early stages of diabetic nephropathy
To address the pathogenic relevance of inflammasome activation in myeloid vs. non-myeloid-derived cells, we next conducted bone marrow transplantation experiments. First, Nlrp3
À / À , caspase-1 À / À , or wild-type (control) bone marrow was transplanted into lethally irradiated db/db mice (age 8 weeks, Figure 7a ). This had no impact on body weight, blood glucose levels (Supplementary Figure S6 online ), or the glomerular frequency of CD11c þ cells (Figure 7b ). Of note, in db/db mice transplanted with Nlrp3 À / À bone marrow no cleaved caspase-1 could be detected in glomerular CD11c þ cells (Figure 7c ). In comparison to control db/db mice albuminuria and FMA increased to the same extend in db/db mice transplanted with Nlrp3
À / À or caspase-1 À / À bone marrow after 12 weeks (Figure 7d and e). Thus, Nlrp3-or caspase1-deficiency in bone marrow-derived cells does not ameliorate diabetic nephropathy in mice.
Next, we conducted the reverse experiment transplanting wild-type bone marrow into Nlrp3 À / À mice to evaluate the role of the Nlrp3 inflammasome in glomerular resident cells ( Figure 7f ). As Nlrp3
À / À mice are not readily available on a 
Inflammasome activation by mitochondrial ROS in diabetic mice
Mitochondrial ROS promote diabetic nephropathy 21, 22 and can trigger Nlrp3-inflammasome activation. 13, 23 To evaluate whether mitochondrial ROS are mechanistically linked with glomerular Nlrp3-dependent inflammasome activation we used the mitochondria-targeted antioxidant MitoTempo, a superoxide dismutase mimetic that accumulates in mitochondria. 24 MitoTempo reduced mitochondrial ROS (Supplementary Figure S7a online ) and in parallel Nlrp3 levels and IL-1b activation in glucose-stressed podocytes (Figure 8a and b) .
Enhanced glycolytic flux is sufficient to increase mitochondrial ROS, but glucose-modified proteins such as AGEs (advanced glycation endproducts) may likewise induce mitochondrial ROS generation through a RAGE (receptor for AGEs)-dependent mechanism. 25 Indeed, AGE-BSA induced Nlrp3 expression and IL-1b cleavage in podocytes, an effect that was prevented by RAGE inhibition (Figure 8a and b) . Thus, glucose and glucose-induced metabolites may synergistically contribute to ROS-dependent inflammasome activation, in particular in the in vivo situation. Of note, MitoTempo failed to reduce levels of cleaved IL-1b in glucose-stressed human podocytes transfected with the constitutive active human Nlrp3 mutant Q705K, 26 indicating ROS triggered Nlrp3-dependent IL-1b maturation in podocytes (Figure 8c) .
To evaluate the role of mitochondrial ROS for inflammasome activation in vivo we next treated db/db and uninephrectomized diabetic C57BL/6 mice (STZ model, STZ mice) with MitoTempo. MitoTempo treatment had no effect on body weight or blood glucose levels (Supplementary Figure S7b online) . In db/db mice, MitoTempo treatment markedly reduced levels of Nlrp3, cleaved IL-1b, albuminuria, and FMA in comparison with control db/db mice (Figure 8d-f) . Likewise, indices of diabetic nephropathy and inflammasome activation were reduced in MitoTempotreated STZ mice when compared with phosphate-buffered saline-treated diabetic controls (Figure 9a-d) .
Genetic ablation of p66 Shc reduces mitochondrial ROS and protects mice from diabetic nephropathy. 21 Again, persistent hyperglycemia failed to induce Nlrp3 expression and IL-1b cleavage in p66
Shc deficient diabetic mice (Figure 10a-c) , supporting a critical role of mitochondrial ROS for inflammasome activation in diabetic nephropathy.
DISCUSSION
Diabetic nephropathy is considered an inflammatory disease, and several reports recently demonstrated inflammasome activation in association with diabetic nephropathy. In the current study we establish that inflammasome activation is causatively linked with diabetic nephropathy. IL-1 receptor antagonism or inhibition of mitochondrial ROS, an established activator of the Nlrp3 inflammasome, ameliorates diabetic nephropathy in mice, suggesting that interventions targeting this mechanism of sterile inflammation may be a feasible therapeutic approach in diabetic nephropathy.
Although originally thought to be specific for the innate immune system, inflammasome activation and signaling has recently been described in cells not belonging to the immune system. 13, 15, 27 Previous to the currently observed hyperglycemiaassociated inflammasome activation in podocytes, similar observations have been made in mice with hyperhomocysteinanemia or diet-induced obesity. 8, 11, 28 In addition to these reports we observed inflammasome activation in glomerular endothelial cells, suggesting that inflammasome activation in various kidney cells may contribute to diabetic nephropathy. Indeed, kidney-restricted silencing of ASC, an adaptor protein required for the inflammasome complex, attenuated proteinuria, albuminuria, and glomerular sclerosis. 8, 11, 28 
To address this question we conducted bone marrowtransplantation experiments, which demonstrated that inflammasome activation in renal resident cells, but not in bone marrow-derived cells, is sufficient to trigger diabetic nephropathy in mice. We acknowledge that the chosen method, bone marrow transplantation, has limitations and that cell-specific inactivation of inflammasome regulators such as Nlrp3 or caspase-1 would be preferred. Cell-specific deletion would likewise enable a researcher to specifically address the role of inflammasome activation in glomerular and tubular cells. However, mice with conditional inactivation of Nlrp3 or caspase-1 are currently not readily available. In addition, inflammasome activation occurred at least in podocytes and endothelial cells. Hence, genetic inflammasome inactivation in multiple renal cell types will be required to address the functional role of inflammasome activation in resident glomerular cells vs. bone marrow-derived cells. Considering these obstacles, we believe that the chosen method constitutes a reasonable approach. In view of the current data, more sophisticated experimental approaches to clarify the role of inflammasome activation in renal resident cells are now justified and required.
Following transplantation of Nlrp3-deficient bone marrow we failed to detect CD11c þ cells with signs of inflammasome activation in renal glomeruli, indicating efficient replacement of renal dendritic cells. This is consistent with the replacement of innate immune cells in tissues such as skin, lung, or liver following bone marrow transplantation. [29] [30] [31] [32] While persistence of some Nlrp3 or caspase-1-expressing innate immune cells in the kidney despite bone marrow transplantation cannot be excluded, the current data argue against a role of inflammasome activation in cells actively recruited from the bone marrow into the kidney during the disease course. This, however, does not exclude a pathogenetic function of bone marrow-derived cells in the course of diabetic nephropathy. Bone marrow-derived cells 
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cl IL-1β may aggravate the disease progression independent of the inflammasome, as previously proposed. 6, 7, 33, 34 In addition, we cannot exclude that inflammasome activation in bone marrow-derived cells contributes to the later disease stages or interstitial tissue damage. On the basis of available data it appears possible that inflammasome activation in renal resident cells including glomerular cells triggers recruitment of bone marrow-derived cells, which then aggravate the disease progression. This possibility has to be experimentally evaluated.
Inflammasome inhibition may be superior to blocking inflammatory cell recruitment 1, 5 as IL-1b and IL-18 impair podocyte and endothelial function independent of inflammatory cell recruitment. 35 Whether modulation of noncanonical functions of Nlrp3, such as the Nlrp3-dependent modulation of Smad2/3 phosphorylation by transforming growth factor-b in tubular cells, 36 will constitute an additional benefit of inflammasome inhibition remains to be evaluated.
The identification of mitochondrial ROS as the Nlrp3 activator in diabetic glomeruli provides a mechanistic link between ROS and sterile inflammation in diabetic nephropathy. 12,21,22,37 ROS-dependent activation of the Nlrp3 inflammasome has been recently described in monocytes and macrophages from diabetic patients, 38 indicating that this pathway is also functional in non-renal cells. Mitochondrial ROS have been proposed as a common pathway mediating Nlrp3 activation. 12, 37 Mitochondrial ROS dissociate TxNIP from thioredoxin, and free TxNIP can bind to and activate Nlrp3. 12, 13, 39 In addition, accumulation of dysfunctional, ROS-generating mitochondria is sufficient to activate the Nlrp3 inflammasome. 12, 13 Although we used two independent approaches to evaluate the relevance of mitochondrial ROS (MitoTempo-and p66
Shc -deficient mice), tools to specifically inhibit ROS in glomerular cells were not available to us. Hence, stringent evidence pinpointing a causative role of glomerular-derived mitochondrial ROS is still pending. À / À mice despite reconstitution with Nlrp3 þ / þ bone marrow (h, i). Mean value±s.e.m. Number of mice (a-e and f-i) in each group is shown in parentheses in a and f; representative periodic acid-Schiff-stained glomeruli in e and i; scale bar ¼ 20 mm (b, c, e, g, and i); white arrows in b and g indicate CD11c þ cells; *Po0.05; **Po0.01. BM, bone marrow; DM, diabetic mice; FMA, fractional mesangial area; IL, interleukin; Nlrp3, nucleotide-binding domain and leucine-rich repeat pyrin 3 domain; NS, not significant; WT, wild type.
Mitochondrial ROS do not only mediate harmful effects but are also required for maintaining cellular homeostasis. 40 This dual function may limit the therapeutic efficacy of mitochondrial-targeted ROS inhibition. Rather, cell-damaging pathways initiated by ROS, but amendable to therapeutic interventions, ought to be identified. Mitochondrial ROS activate the inflammasome, and inhibition of inflammasome signaling using anakinra provided nephroprotection and even reversed diabetic nephropathy in the current study, whereas inhibition of mitochondrial ROS using MitoTempo was only partially protective. Thus, inflammasome inhibition, which is already clinically established, 17 constitutes a feasible therapeutic target.
Inflammasome inhibition in diabetic patients may provide additional benefits due to its metabolic effects. 19 ,20,41 Indeed, we observed a reduction in body weight and blood glucose levels in db/db mice. Yet, anakinra conveyed nephropection not only in db/db mice, but also in mice with STZ-induced insulinopenia and hyperglycemia (reflecting type 1 diabetes). Hence, nephroprotection by inflammasome inhibition is at least partially independent of these metabolic effects. The efficacy, feasibility, and safety of inflammasome inhibition in patients with diabetic nephropathy, potentially using small molecule inhibitors, 42 remains to be evaluated.
The current findings extend recent studies imputing an immune modulatory function to podocytes. [43] [44] [45] [46] Thus, besides inflammasome activation 8, 11 (and current study) podocytes are competent to signal via TLR, 44, 45 to modulate complement, 43, 46, 47 and to activate naive T cells following antigen presentation. 45 The ability of podocytes to sense danger signals and to initiate an immune response may render the glomerular filtration barrier not only sensitive to inflammatory disease, but in addition endow the kidney, which continuously controls a large portion of the body's blood, with an immune-surveillance function, reminiscent of the dual function of teleost's kidneys. 48 These immunological functions may be pathologically relevant not only in infectious or autoimmune diseases. 49 Rather, the current and previous studies 50 suggest that sterile inflammation in the kidney may be of pathogenic relevance in the context of metabolic diseases. This may lay ground for novel therapeutic approaches to nephropathies associated with metabolic diseases.
MATERIALS AND METHODS
See online Supplementary materials for additional information.
Mice Caspase1 À / À , db/db (Lepr db/db), and nondiabetic db/m control mice (C57BL/6J background) were obtained from Jackson Laboratories, Bar Harbor, ME. p66
shc À / À and Nlrp3 À / À mice have been previously described. 21, 51, 52 In the current study we used littermates that have been backcrossed for at least 10 generations on a C57BL/6 or C57BL/6J background. All animal experiments were conducted following standards and procedures approved by the local Animal Care and Use Committee (Landesverwaltungsamt Halle, Germany).
Diabetic nephropathy models
Two different STZ-dependent models of diabetic nephropathy were used in the current study. A long-term model (24 weeks) following a previously published protocol 21, 46, 53, 54 was used in genetically modified p66
Shc À / À mice and their controls. In these mice, persistent hyperglycemia was induced by intraperitoneal administration of 60 mg/kg STZ freshly dissolved in 0.05 mol/l sterile sodium citrate at pH 4.5 for 5 consecutive days in 8-week-old mice, as described. 21, 46, 53, 54 In addition we used the unilateral nephrectomy model of diabetic nephropathy. 21, 55 This short-term model is particularly useful to test therapeutic interventions. Briefly, 8-week-old mice were anesthetized with pentobarbital (1 mg/kg body weight, intraperitoneally). A dorso-lumbar incision (approximately 1 cm) was made and the ureter, the renal artery, and renal vein were ligated and subsequently severed. The kidney was removed and the incision was sutured. Two weeks after surgery, diabetes was induced by injections of STZ (intraperitoneally, 40 mg/kg body weight, freshly dissolved in 0.05 mol/l sterile sodium citrate, pH 4.5) for 5 consecutive days. Age-matched control mice received 100 ml phosphate-buffered saline intraperitoneally for 5 consecutive days.
In both models mice were considered diabetic if blood glucose levels were above 300 mg/dl 16 d after the last STZ injection. 21, 53, 54 Blood glucose levels were determined from blood samples taken from the tail vein by using ACCU-CHEK glucose strips. In the first 3 weeks after the onset of diabetes, blood glucose values were measured three times per week, and thereafter once per week. 21, 53, 54 Mice with blood glucose levels above 500 mg/dl received 1-2 U of insulin (Lantus) to avoid excessive and potentially lethal hyperglycemia. 21, 53, 54 Blood and tissue samples were obtained after 24 weeks (long-term model) or 8 weeks (short-term model) of persistent hyperglycemia in diabetic mice. Age-matched littermates served as controls.
In vivo intervention studies A subset of mice was treated with the IL-1R antagonist (Anakinra, 10 mg/kg, intraperitoneally) 56 or the mitochondria-targeted antioxidant MitoTempo (700 mg/kg body weight per day; subcutaneous). 57 Interventions with Anakinra or MitoTempo were initiated in 8-week-old db/db mice to determine its preventive effect. In uninephrectomized, STZ-treated mice, treatment with Anakinra or MitoTempo was initiated 2 weeks after establishment of stable hyperglycemia and continued for 8 weeks. Treatment with anakinra was initiated in 12-week-old db/db mice to determine its effect after onset of diabetic nephropathy. Control mice were injected with phosphate-buffered saline.
Analyses of human samples
Patients (N ¼ 87) with type 2 diabetes, according to the American Diabetes Association criteria, 58 were recruited from the diabetes outpatient clinic at the University Hospital Heidelberg. Microalbuminuria was diagnosed if at least two separate urine samples out of three consecutive urine samples (albumin excretion rate AERX30 mg/24 h) were positive. Nondiabetic control subjects (N ¼ 33) were recruited at the outpatient clinic of the University Hospital Heidelberg and Magdeburg. Nondiabetic controls had either stable and minor osteoporosis or stable and well-controlled thyroid function (e.g., after thyreoidectomy). Nondiabetic controls were on vitamin D and calcium substitution only (osteoporosis patients) or thyroid hormones, but no other medication. All patients and controls were Caucasian. The study complied with the Declaration of Helsinki; all patients entered the study according to the guidelines of the local ethics committees after giving informed consent (Ethic-Committee-No: 204/2004).
Statistical analysis
The data are summarized as the mean ± s.e.m. (standard error of the mean). Statistical analyses were performed with Student's t-test and analysis of variance. Post-hoc comparisons of analysis of variance were corrected with the method of Tukey. For the patient data, Pearson's correlation coefficient (r) was determined and the twotailed P-value is given. The correlation was corrected for age, sex, disease duration, and estimated glomerular filtration rate by multiple regression analysis. StatistiXL 
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